Cite
HARVARD Citation
Pelz, A. et al. (2018). S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset. European journal of immunology. 48 (3), pp. 498-508. [Online].